Morphine/naltrexone
Combination of
Morphine sulfateOpioid
NaltrexoneOpioid antagonist
Clinical data
Trade namesEmbeda
AHFS/Drugs.comembeda
Routes of
administration
Oral
Legal status
Legal status
Identifiers
CAS Number
  • 1131418-84-2
  (verify)

The drug combination morphine/naltrexone (trade name Embeda) is an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain.[1] The active ingredients are morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule 2 controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.[2]

King Pharmaceuticals temporarily recalled Embeda in 2011 after complaints from the FDA in regard to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential.[3]

Embeda became available again some years later.[4]

See also

References

  1. ^ "Medication guide" (PDF). www.fda.gov.
  2. ^ "SAVE ON YOUR EMBEDA PRESCRIPTION - Embeda". www.embeda.com.
  3. ^ Eustice C (15 March 2011). "Chronic Pain Drug Embeda Recalled". About.com. Archived from the original on 15 March 2012.
  4. ^ Shye R (31 October 2014). "Embeda Is Back: New Pain Med with Improved Safety". GoodRx, Inc.